Abstracts tagged "Bisphosphonates"

Abstract Number: 1850 • 2017 ACR/ARHP Annual Meeting
Efficacy of Zoledronic Acid and Denosumab in the Treatment of Patients with Low Back Pain and Modic Changes: A Proof of Principle Trial
Guoqi Cai¹, Laura Laslett¹, Dawn Aitken², Andrew Halliday³, Feng Pan², Petr Otahal¹, Deb Speden⁴, Tania Winzenberg¹ and Graeme Jones², ¹Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, ²Musculoskeletal Unit, Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, ³Radiology, Royal Hobart Hospital, Hobart, Australia, ⁴Royal Hobart Hospital, Hobart, Australia
Background/Purpose: Low back pain (LBP) is a common and debilitating problem. There are currently very limited pharmacological treatments for LBP. Vertebral endplate subchondral bone abnormalities…
Abstract Number: 2390 • 2017 ACR/ARHP Annual Meeting
Trends and Predictors of Guideline Adherence for Glucocorticoid-Induced Osteoporosis Prevention in an Early Rheumatoid Arthritis Cohort
Stephanie Gottheil¹, Orit Schieir², Carter Thorne³, Carol A Hitchon⁴, Diane Tin⁵, Edward C. Keystone⁶, Gilles Boire⁷, Boulos Haraoui⁸, Susan J. Bartlett⁹, Vivian P. Bykerk¹⁰ and Janet E. Pope¹¹, ¹University of Western Ontario, LONDON, ON, Canada, ²McGill University, Montreal, ON, Canada, ³University of Toronto, Newmarket, ON, Canada, ⁴University of Manitoba, Winnipeg, MB, Canada, ⁵The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁶Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁷Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁸Institute de Rheumatologie, Montreal, QC, Canada, ⁹Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ¹⁰2-005, Mt Sinai Hospital, Toronto, ON, Canada, ¹¹Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada
Background/Purpose: RA patients are at a high risk of osteoporosis and fracture, in part due to frequent glucocorticoid use. Despite recommendations from ACR guidelines on…
Abstract Number: 48 • 2017 ACR/ARHP Annual Meeting
Modulation of Subchondral Bone Turnover Is Associated with Alteration of Cartilage Tissue Quality
Cedric Lavet, Isabelle Badoud and Patrick Ammann, Division of Bone Diseases, Geneva, Switzerland
Background/Purpose: Osteochondral unit is a bio composite responsible for an optimal distribution of load during movements and axial compression of a joint. Any alteration of…
Abstract Number: 320 • 2017 ACR/ARHP Annual Meeting
Teriparatide Compared with Risedronate and the Risk of Clinical Vertebral Fractures: 2-Year Results of a Randomized, Double-Dummy Clinical Trial
Cristiano A.F Zerbini¹, Piet Geusens², Eric Lespessailles³, Jean-Jacques Body⁴, Enrique Casado⁵, Jan Stepan⁶, David L Kendler⁷, Luis Russo⁸, Susan L. Greenspan⁹, Salvatore Minisola¹⁰, Alicia Bagur¹¹, Peter Lakatos¹², Astrid Fahrleitner-Pammer¹³, Rüdiger Möricke¹⁴, Pedro Lopez-Romero¹⁵ and Fernando Marin¹⁶, ¹Centro Paulista de Investigações Clinicas, São Paulo, Brazil, ²Maastricht University Hospital, Maastricht, Netherlands, ³Service de Rhumatologie, CHR d'Orléans, Orléans, France, ⁴CHU Brugmann, Free University Brussels, Brussels, Belgium, ⁵Rheumatology, University Hospital Parc Taulí, Sabadell, Spain, ⁶Institute of Rheumatology, Faculty of Medicine 1, Charles University, Prague, Czech Republic, ⁷University of British Columbia, Vancouver, BC, Canada, ⁸Centro de Analises e Pesquisas Clínicas LTDA,, Rio de Janeiro, Brazil, ⁹University of Pittsburgh, Pittsburgh, PA, ¹⁰Internal Medicine, Policlinico Umberto I,, Rome, Italy, ¹¹Centro de Osteopatías Comlit, Buenos Aires, Argentina, ¹²Department of Medicine, Semmelweis University, Budapest, Hungary, ¹³Division of Endocrinology, Medical University, Graz, Austria, ¹⁴Institut Präventive Medizin & Klinische Forschung, Magdeburg, Germany, ¹⁵Europe Research Center, Eli Lilly and Company, Madrid, Spain, ¹⁶Lilly Research Center Europe, Madrid, Spain
Background/Purpose: The VERO trial was an active-controlled fracture endpoint clinical trial that recruited postmenopausal women with low bone mass and prevalent vertebral fractures (VFx). We…
Abstract Number: 321 • 2017 ACR/ARHP Annual Meeting
A Meta-Analysis of 4 Clinical Trials of Denosumab Compared with Bisphosphonates in Postmenopausal Women Previously Treated with Oral Bisphosphonates
Paul D Miller¹, N Pannacciulli², J Malouf³, A Singer⁴, E Czerwinski⁵, HG Bone⁶, C Wang², Rachel B. Wagman² and JP Brown⁷, ¹Colorado Center for Bone Research, Lakewood, CO, ²Amgen Inc., Thousand Oaks, CA, ³Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁴Georgetown University Medical Center, Washington, DC, ⁵Krakow Medical Center, Krakow, Poland, ⁶Michigan Bone and Mineral Clinic, Detroit, MI, ⁷CHU de Québec Research Centre and Laval University, Québec, QC, Canada
Background/Purpose: Four clinical trials have separately shown greater BMD gains with transitioning to denosumab (DMAb) compared with continuing on bisphosphonates (BP) in subjects previously treated…
Abstract Number: 325 • 2017 ACR/ARHP Annual Meeting
Zoledronic Acid Did Not Impaired Renal Function in Patients with Osteoporosis
Ying-Chou Chen Sr., Division of Rheumatology, Allergy and Immunology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung County, Taiwan
Background/Purpose: Bisphosphonates are recommended for patients with osteoporosis, however concerns have been raised with regards to their effect on kidney function. The aim of this…
Abstract Number: 117 • 2017 Pediatric Rheumatology Symposium
The Effect of Bisphosphonate Use on Bone Density Measurements in Patients with Muscular Dystrophy
Simrat Morris^1,2, Syeda Maqsood³, Christine Garapic³, Andre Prochoroff³ and Hulya Bukulmez³, ¹Rainbow Babies and Childrens Hospital, Cleveland, OH, ²University Hospitals Cleveland Medical Center, Cleveland, OH, ³MetroHealth Medical Center, Cleveland, OH
Background/Purpose: Individuals with Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy have impaired bone health and increased fracture risk due to several factors including immobility,…
Abstract Number: 21 • 2016 ACR/ARHP Annual Meeting
Outcomes of Rheumatoid Arthritis Patients with Hip Fracture
Lucy Liu¹, Joan Lo² and Malini Chandra³, ¹Internal Medicine, Kaiser Permanente, Oakland, CA, ²Endocrinology, Kaiser Permanente, Oakland, CA, ³Kaiser Permanente, Oakland, CA
Background/Purpose: Rheumatoid arthritis (RA) is a well-known risk factor for osteoporosis and hip fracture. Recent studies suggest RA patients fracture at a younger age and…
Abstract Number: 327 • 2016 ACR/ARHP Annual Meeting
Drug Retention Rate of Oral Bisphosphonate in Patients with Rheumatoid Arthritis
Ji-Heh Park¹, Seung-Geun Lee¹, Eun-Kyoung Park², Hee-Sang Tag³ and Geun-Tae Kim⁴, ¹Internal Medicine, Pusan National University School of Medicine, Pusan National University Hospital, Busan, Korea, The Republic of, ²Division of Rheumatology, Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea, The Republic of, ³Division of Rheumatology, Department of Internal Medicine, Kosin University College of Medicine, Busan, South Korea, ⁴Kosin University College of Medicine, Busan, South Korea
Background/Purpose: As rheumatoid arthritis (RA) is a well-established risk factor for osteoporosis and compression fracture, non-adherence to bisphosphonate (BP) therapy in patients with RA can…
Abstract Number: 348 • 2016 ACR/ARHP Annual Meeting
Bisphosphonates-Related Atypical Femur Fractures: 8 Years’ Experience in a Single Center
JungHee Koh¹, Seo Hwa Kim², Haneul Kim³, Min Kyung Chung³, Ji Hyeon Ju⁴ and Sung-Hwan Park⁴, ¹Seochogu, Banpodaero, 222, Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ²Division of Rheumatology,, Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, The Republic of, ³Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, The Republic of, ⁴Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Patients with rheumatoid arthritis (RA) are diagnosed with osteoporosis earlier than those without, and are therefore exposed to bisphosphonates for longer. However, the increasing…
Abstract Number: 349 • 2016 ACR/ARHP Annual Meeting
Effects of Osteoporosis Treatments for Bone Loss and Pain-Related Behavior in the Hind Limb-Unloaded Mouse Model of Disuse Osteoporosis
Gaku Miyamura¹, Hiroki Wakabayashi², Taro Nakagawa³, Sho Kato², Yohei Naito⁴ and Akihiro Sudo⁵, ¹Department of Orthopaedic surgery, Graduate School of Medicine, Mie University, Tsu,Mie, Japan, ²Department of Orthopaedic Surgery, Graduate School of Medicine, Mie University, Tsu City, Japan, ³Department of Orthopaedic surgery, Graduate School of Medicine, Mie University, Tsu, Japan, ⁴Department of Orthopaedic Surgery, Graduate School of Medicine, Mie University, Tsu City, Mie, Japan, ⁵Department of Orthopaedic surgery, Graduate School of Medicine, Mie University, Tsu-city, Japan
Background/Purpose: Osteoporotic patients with no evidence of fractures sometimes experience vague lower back pain. However, there have been few reports regarding the correlation between…
Abstract Number: 738 • 2016 ACR/ARHP Annual Meeting
Preventive Effect of Combined Treatment with Bisphosphonate and Vitamin D on Atherosclerosis in Patients with Systemic Lupus Erythematosus
Kazumasa Ohmura, Masaru Kato, Toshiyuki Watanabe, Ryo Hisada, Masatoshi Kanda, Sanae Shimamura, Ikuma Nakagawa, Yuka Shimizu, Kenji Oku, Toshiyuki Bohgaki, Olga Amengual, Tetsuya Horita, Shinsuke Yasuda and Tatsuya Atsumi, Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Background/Purpose: Premature atherosclerosis is one of the major complications of systemic lupus erythematosus (SLE). Preventing atherosclerosis is a key objective while monitoring patients with SLE.…
Abstract Number: 1025 • 2016 ACR/ARHP Annual Meeting
Assessment of the Effects of Switching Bisphosphonates to Denosumab or Daily Teriparatide in Patients with Rheumatoid Arthritis
Kosuke Ebina¹, Makoto Hirao², Jun Hashimoto³, Masao Yukioka⁴, Takaaki Noguchi⁵ and Hideki Yoshikawa⁶, ¹Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan, ²Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Suita, Japan, ³Dept of Rheumatology, Osaka-Minami Medical Center, Kawachinagano City, Japan, ⁴Orthopedic Surgery, Yukioka Hospital, Osaka, Japan, ⁵Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Osaka, Japan, ⁶Department of Orthopedics, Osaka University Graduate School of Medicine, Suita Osaka, Japan
Background/Purpose: The efficacies of switching bisphosphonate (BP) to denosumab (DMAb), an anti-RANKL antibody which strongly inhibits bone resorption, or daily teriparatide (TPTD), a bone anabolic…
Abstract Number: 2387 • 2016 ACR/ARHP Annual Meeting
Response to Pamidronate Treatment Assessed By Whole Body Magnetic Resonance Imaging in Pediatric Chronic Non-Bacterial Osteomyelitis
Caroline Marie Andreasen¹, Anne Grethe Jurik², Mia Glerup³, Christian Høst⁴, Birgitte Thorsted Mahler⁴, Ellen-Margrethe Hauge⁵ and Troels Herlin⁶, ¹Dept. Rheumatology, Dept. of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ²Dept. of Radiology, Aarhus University Hospital, Aarhus, Denmark, ³Pediatric Rheumatology Clinic, Department of Pediatrics, Dept. of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, ⁴Dept. of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, ⁵Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁶Dept. of Pediatrics, Aarhus University Hospital, Aarhus N, Denmark
Background/Purpose: Pamidronate (PAM) may be effective in diminishing pain and permanent bone deformities in chronic non-bacterial osteomyelitis (CNO). Whole body magnetic resonance imaging (WB MRI)…
Abstract Number: 372 • 2015 ACR/ARHP Annual Meeting
Prevalence of Atypical Fractures in a Tertiary Hospital
Miren Uriarte Ecenarro, Nerea Errazquin Aguirre, César Antonio Egües Dubuc, Carlos Francisco Meneses Villalba, Vicente Aldasoro Caceres, Joaquin Belzunegui Otano and Gaspar De la Herran, Donostia University Hospital, San Sebastian, Spain
Background/Purpose: Actually, Biphosphonates are considered the first line treatment for osteoporosis. One of the side effects of the continuous treatment with these drugs is the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].